Smith & Wesson Brands’s Earnings: A Preview

Smith & Wesson Brands (NASDAQ:SWBI) is set to give its latest quarterly earnings report on Thursday, 2023-12-07. Here’s…

Smith & Wesson Brands (NASDAQ:SWBI) is set to give its latest quarterly earnings report on Thursday, 2023-12-07. Here’s what investors need to know before the announcement.

Analysts estimate that Smith & Wesson Brands will report an earnings per share (EPS) of $0.14.

Smith & Wesson Brands bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.08, which was followed by a 10.85% increase in the share price the next day.

Here’s a look at Smith & Wesson Brands’s past performance and the resulting price change:

Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023
EPS Estimate 0.05 0.27 0.22 0.40
EPS Actual 0.13 0.32 0.25 0.26
Price Change % 10.85% 20.2% 6.16% -19.58%

eps graph

Stock Performance

Shares of Smith & Wesson Brands were trading at $14.11 as of December 04. Over the last 52-week period, shares are up 45.61%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Smith & Wesson Brands visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

Hemp-focused consumer wellness company CV Sciences, Inc. (OTCQB: CVSI) announced on Thursday its financial results for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter gross margin was 45.8%, representing a sequential improvement from 45.1% in the third quarter. "Our 2023 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow," Joseph Dowling, CEO of CV Sciences, said. "As the CBD category consolidates, we have increased our market share in key sales channels, including the natural product retail channel. We will continue to focus our resources on new product development, as evidenced by our pet line expansion with our recent launch of pet chews for hip and joint health and calming care."

CVSI